• Je něco špatně v tomto záznamu ?

Worse Health-Related Quality of Life at long-term follow-up in patients with Cushing's disease than patients with cortisol producing adenoma. Data from the ERCUSYN

E. Valassi, R. Feelders, D. Maiter, P. Chanson, M. Yaneva, M. Reincke, M. Krsek, M. Tóth, SM. Webb, A. Santos, I. Paiva, I. Komerdus, M. Droste, A. Tabarin, CJ. Strasburger, H. Franz, PJ. Trainer, J. Newell-Price, JA. Wass, E. Papakokkinou, O....

. 2018 ; 88 (6) : 787-798. [pub] 20180416

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19045517

OBJECTIVE: Hypercortisolism in Cushing's syndrome (CS) is associated with impaired health-related quality of life (HRQoL), which may persist despite remission. We used the data entered into the European Registry on Cushing's syndrome (ERCUSYN) to evaluate if patients with CS of pituitary origin (PIT-CS) have worse HRQoL, both before and after treatment than patients with adrenal causes (ADR-CS). METHODS: Data from 595 patients (492 women; 83%) who completed the CushingQoL and/or EQ-5D questionnaires at baseline and/or following treatment were analysed. RESULTS: At baseline, HRQoL did not differ between PIT-CS (n = 293) and ADR-CS (n = 120) on both EuroQoL and CushingQoL. Total CushingQoL score in PIT-CS and ADR-CS was 41 ± 18 and 44 ± 20, respectively (P = .7). At long-time follow-up (>1 year after treatment) total CushingQoL score was however lower in PIT-CS than ADR-CS (56 ± 20 vs 62 ± 23; P = .045). In a regression analysis, after adjustment for baseline age, gender, remission status, duration of active CS, glucocorticoid dependency and follow-up time, no association was observed between aetiology and HRQoL. Remission was associated with better total CushingQoL score (P < .001), and older age at diagnosis with worse total score (P = .01). Depression at diagnosis was associated with worse total CushingQoL score at the last follow-up (P < .001). CONCLUSION: PIT-CS patients had poorer HRQoL than ADR-CS at long-term follow-up, despite similar baseline scoring. After adjusting for remission status, no interaetiology differences in HRQoL scoring were found. Age and presence of depression at diagnosis of CS may be potential predictors of worse HRQoL regardless of CS aetiology.

2nd Department of Medicine 3rd Faculty of Medicine Charle University and University Hospital Kralovske Vinohrady Prague Czech Republic

2nd Department of Medicine Semmelweis University Budapest Hungary

Academic Unit of Diabetes Endocrinology and Reproduction Department of Oncology and Metabolism The Medical School University of Sheffield Sheffield UK

Centre Hospitalier Universitaire de Bordeaux Bordeaux France

Department of Endocrinology Christie Hospital Manchester UK

Division of Clinical Endocrinology Department of Medicine CCM Charité Universitätsmedizin Berlin Germany

Erasmus University Medical Centre Rotterdam The Netherlands

Hospitais da Universidade de Coimbra Coimbra Portugal

IIB Sant Pau and Department of Endocrinology Medicine Hospital Sant Pau UAB and Centro de Investigación Biomédica en Red de Enfermedades Raras ISCIII Barcelona Spain

Institute of Medicine at Sahlgrenska Academy University of Gothenburg and the Department of Endocrinology Sahlgrenska University Hospital Gothenburg Sweden

Lohmann and Birkner Health Care Consulting GmbH Berlin Germany

Medical University of Sofia Sofia Bulgary

Medizinische Klinik und Poliklinik 4 Klinikum der Universität München München Germany

Moscow Regional Research Clinical Institute n a Vladimirsky Moscow Russia

Oxford Radcliffe Hospitals NHS Trust Oxford UK

Praxis für Endokrinologie Droste Oldenburg Germany

UCL Cliniques universitaires St Luc Brussels Belgium

Univ Paris Sud Université Paris Saclay UMR S1185 Paris France Assistance Publique Hôpitaux de Paris Hôpital de Bicêtre Service de Endocrinologie et des Maladies de la Reproduction Paris France Institut National de la Santé et de la Recherche Médicale U1185 Paris France

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19045517
003      
CZ-PrNML
005      
20220809115111.0
007      
ta
008      
200109s2018 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/cen.13600 $2 doi
035    __
$a (PubMed)29574994
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Valassi, Elena $u IIB-Sant Pau and Department of Endocrinology/Medicine, Hospital Sant Pau, UAB, and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER, Unidad 747), ISCIII, Barcelona, Spain.
245    10
$a Worse Health-Related Quality of Life at long-term follow-up in patients with Cushing's disease than patients with cortisol producing adenoma. Data from the ERCUSYN / $c E. Valassi, R. Feelders, D. Maiter, P. Chanson, M. Yaneva, M. Reincke, M. Krsek, M. Tóth, SM. Webb, A. Santos, I. Paiva, I. Komerdus, M. Droste, A. Tabarin, CJ. Strasburger, H. Franz, PJ. Trainer, J. Newell-Price, JA. Wass, E. Papakokkinou, O. Ragnarsson, ERCUSYN Study Group,
520    9_
$a OBJECTIVE: Hypercortisolism in Cushing's syndrome (CS) is associated with impaired health-related quality of life (HRQoL), which may persist despite remission. We used the data entered into the European Registry on Cushing's syndrome (ERCUSYN) to evaluate if patients with CS of pituitary origin (PIT-CS) have worse HRQoL, both before and after treatment than patients with adrenal causes (ADR-CS). METHODS: Data from 595 patients (492 women; 83%) who completed the CushingQoL and/or EQ-5D questionnaires at baseline and/or following treatment were analysed. RESULTS: At baseline, HRQoL did not differ between PIT-CS (n = 293) and ADR-CS (n = 120) on both EuroQoL and CushingQoL. Total CushingQoL score in PIT-CS and ADR-CS was 41 ± 18 and 44 ± 20, respectively (P = .7). At long-time follow-up (>1 year after treatment) total CushingQoL score was however lower in PIT-CS than ADR-CS (56 ± 20 vs 62 ± 23; P = .045). In a regression analysis, after adjustment for baseline age, gender, remission status, duration of active CS, glucocorticoid dependency and follow-up time, no association was observed between aetiology and HRQoL. Remission was associated with better total CushingQoL score (P < .001), and older age at diagnosis with worse total score (P = .01). Depression at diagnosis was associated with worse total CushingQoL score at the last follow-up (P < .001). CONCLUSION: PIT-CS patients had poorer HRQoL than ADR-CS at long-term follow-up, despite similar baseline scoring. After adjusting for remission status, no interaetiology differences in HRQoL scoring were found. Age and presence of depression at diagnosis of CS may be potential predictors of worse HRQoL regardless of CS aetiology.
650    _2
$a adenom $x farmakoterapie $x metabolismus $x patofyziologie $7 D000236
650    _2
$a dospělí $7 D000328
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a glukokortikoidy $x terapeutické užití $7 D005938
650    _2
$a lidé $7 D006801
650    _2
$a hydrokortison $x metabolismus $7 D006854
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a hypersekrece ACTH v hypofýze $x farmakoterapie $x metabolismus $x patofyziologie $7 D047748
650    _2
$a prospektivní studie $7 D011446
650    _2
$a kvalita života $7 D011788
650    _2
$a průzkumy a dotazníky $7 D011795
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Feelders, Richard $u Erasmus University Medical Centre, Rotterdam, The Netherlands.
700    1_
$a Maiter, Dominique $u UCL Cliniques universitaires St Luc, Brussels, Belgium.
700    1_
$a Chanson, Philippe $u Univ Paris-Sud, Université Paris-Saclay UMR-S1185, Paris, France. Assistance Publique-Hôpitaux de Paris, Hôpital de Bicêtre, Service de Endocrinologie et des Maladies de la Reproduction, Paris, France. Institut National de la Santé et de la Recherche Médicale U1185, Paris, France.
700    1_
$a Yaneva, Maria $u Medical University of Sofia, Sofia, Bulgary.
700    1_
$a Reincke, Martin $u Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, München, Germany.
700    1_
$a Krsek, Michal $u 2nd Department of Medicine, 3rd Faculty of Medicine, Charle University and University Hospital Kralovske Vinohrady, Prague, Czech Republic.
700    1_
$a Tóth, Miklós $u 2nd Department of Medicine, Semmelweis University, Budapest, Hungary.
700    1_
$a Webb, Susan M $u IIB-Sant Pau and Department of Endocrinology/Medicine, Hospital Sant Pau, UAB, and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER, Unidad 747), ISCIII, Barcelona, Spain.
700    1_
$a Santos, Alicia $u IIB-Sant Pau and Department of Endocrinology/Medicine, Hospital Sant Pau, UAB, and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER, Unidad 747), ISCIII, Barcelona, Spain.
700    1_
$a Paiva, Isabel $u Hospitais da Universidade de Coimbra, Coimbra, Portugal.
700    1_
$a Komerdus, Irina $u Moscow Regional Research Clinical Institute n.a. Vladimirsky, Moscow, Russia.
700    1_
$a Droste, Michael $u Praxis für Endokrinologie Droste, Oldenburg, Germany.
700    1_
$a Tabarin, Antoine $u Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.
700    1_
$a Strasburger, Christian J. $u Division of Clinical Endocrinology, Department of Medicine CCM, Charité- Universitätsmedizin, Berlin, Germany. $7 xx0275498
700    1_
$a Franz, Holger $u Lohmann & Birkner Health Care Consulting GmbH, Berlin, Germany.
700    1_
$a Trainer, Peter J $u Department of Endocrinology, Christie Hospital, Manchester, UK.
700    1_
$a Newell-Price, John $u Academic Unit of Diabetes, Endocrinology and Reproduction, Department of Oncology and Metabolism, The Medical School, University of Sheffield, Sheffield, UK.
700    1_
$a Wass, John Ah $u Oxford Radcliffe Hospitals NHS Trust, Oxford, UK.
700    1_
$a Papakokkinou, Eleni $u Institute of Medicine at Sahlgrenska Academy, University of Gothenburg and the Department of Endocrinology, Sahlgrenska University Hospital, Gothenburg, Sweden.
700    1_
$a Ragnarsson, Oskar $u Institute of Medicine at Sahlgrenska Academy, University of Gothenburg and the Department of Endocrinology, Sahlgrenska University Hospital, Gothenburg, Sweden.
710    2_
$a ERCUSYN Study Group
773    0_
$w MED00009474 $t Clinical endocrinology $x 1365-2265 $g Roč. 88, č. 6 (2018), s. 787-798
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29574994 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20220809115108 $b ABA008
999    __
$a ok $b bmc $g 1483785 $s 1084190
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 88 $c 6 $d 787-798 $e 20180416 $i 1365-2265 $m Clinical endocrinology $n Clin Endocrinol (Oxf) $x MED00009474
LZP    __
$a Pubmed-20200109

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...